| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥5.95B | ¥5.03B | +18.4% |
| Cost of Sales | ¥4.03B | ¥3.37B | +19.5% |
| Gross Profit | ¥1.92B | ¥1.66B | +16.0% |
| SG&A Expenses | ¥571M | ¥533M | +7.2% |
| Operating Income | ¥1.35B | ¥1.12B | +20.2% |
| Non-operating Income | ¥7M | ¥78M | -90.8% |
| Non-operating Expenses | ¥19M | ¥3M | +511.8% |
| Ordinary Income | ¥1.34B | ¥1.20B | +11.7% |
| Profit Before Tax | ¥1.34B | ¥1.20B | +11.6% |
| Income Tax Expense | ¥449M | ¥406M | +10.5% |
| Net Income | ¥892M | ¥795M | +12.2% |
| Net Income Attributable to Owners | ¥891M | ¥794M | +12.2% |
| Total Comprehensive Income | ¥901M | ¥768M | +17.3% |
| Interest Expense | ¥4M | ¥3M | +45.1% |
| Basic EPS | ¥21.18 | ¥18.87 | +12.2% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥25.05B | ¥26.53B | ¥-1.48B |
| Cash and Deposits | ¥12.96B | ¥14.92B | ¥-1.96B |
| Accounts Receivable | ¥4.01B | ¥3.58B | +¥435M |
| Inventories | ¥2.13B | ¥2.12B | +¥4M |
| Non-current Assets | ¥9.47B | ¥9.59B | ¥-113M |
| Item | Value |
|---|---|
| Net Profit Margin | 15.0% |
| Gross Profit Margin | 32.3% |
| Current Ratio | 542.8% |
| Quick Ratio | 496.7% |
| Debt-to-Equity Ratio | 0.22x |
| Interest Coverage Ratio | 314.78x |
| Effective Tax Rate | 33.5% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +18.4% |
| Operating Income YoY Change | +20.1% |
| Ordinary Income YoY Change | +11.6% |
| Net Income Attributable to Owners YoY Change | +12.2% |
| Total Comprehensive Income YoY Change | +17.3% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 42.12M shares |
| Treasury Stock | 1K shares |
| Average Shares Outstanding | 42.12M shares |
| Book Value Per Share | ¥673.05 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥0.00 |
| Year-End Dividend | ¥16.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DrugSubstanceSales | ¥4.04B | ¥841M |
| PharmaceuticalMarketing | ¥2.23B | ¥549M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥25.70B |
| Operating Income Forecast | ¥5.43B |
| Ordinary Income Forecast | ¥5.43B |
| Net Income Attributable to Owners Forecast | ¥3.64B |
| Basic EPS Forecast | ¥86.42 |
| Dividend Per Share Forecast | ¥0.00 |
| Property, Plant & Equipment | ¥9.10B | ¥9.20B | ¥-93M |
| Intangible Assets | ¥8M | ¥9M | ¥-527,000 |
| Investment Securities | ¥100M | ¥90M | +¥10M |
| Total Assets | ¥34.52B | ¥36.11B | ¥-1.59B |
| Current Liabilities | ¥4.61B | ¥6.36B | ¥-1.75B |
| Accounts Payable | ¥1.74B | ¥1.57B | +¥175M |
| Short-term Loans | ¥860M | ¥860M | ¥0 |
| Non-current Liabilities | ¥1.56B | ¥1.63B | ¥-72M |
| Long-term Loans | ¥1.17B | ¥1.24B | ¥-72M |
| Total Liabilities | ¥6.17B | ¥7.99B | ¥-1.82B |
| Total Equity | ¥28.35B | ¥28.12B | +¥228M |
| Capital Stock | ¥1.34B | ¥1.34B | ¥0 |
| Capital Surplus | ¥1.02B | ¥1.02B | ¥0 |
| Retained Earnings | ¥25.95B | ¥25.73B | +¥218M |
| Treasury Stock | ¥-484,000 | ¥-484,000 | ¥0 |
| Owners' Equity | ¥28.35B | ¥28.12B | +¥228M |
| Working Capital | ¥20.43B | - | - |